Imatinib
|
|
|
- CAS-Nr.
- 152459-95-5
- Englisch Name:
- Imatinib
- Synonyma:
- Imatinib Mesilate;matinib;4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE;IMA-3;Veenat;ST-1571;CS-1955;IMATINIB;lmatinib;CGP057148B
- CBNumber:
- CB7370890
- Summenformel:
- C29H31N7O
- Molgewicht:
- 493.6
- MOL-Datei:
- 152459-95-5.mol
|
Imatinib Eigenschaften
- Schmelzpunkt:
- 208-210°C (dec.)
- Dichte
- 1?+-.0.06 g/cm3(Predicted)
- storage temp.
- Keep in dark place,Sealed in dry,Store in freezer, under -20°C
- L?slichkeit
- DMSO (Slightly, Heated), Methanol (Slightly, Heated)
- pka
- pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52(at 25℃)
- Aggregatzustand
- Solid
- Farbe
- White to Pale Beige
- Merck
- 14,4902
- CAS Datenbank
- 152459-95-5(CAS DataBase Reference)
Imatinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Chemische Eigenschaften
Orange Solid
Verwenden
Imatinib impurity.
Indications
Bcr-Abl inhibitor imatinib (Gleevec(R), Novartis) was approved in 2001 by the FDA. Although fasudil was approved in 1995, imatinib is widely perceived as the first approved SMKI mainly owing to the fact that fasudil's kinase inhibitory mechanism was unknown at the time of approval, and efforts to gain approval of fasudil have been unsuccessful in the United States and Europe.
The field of kinase inhibitor development has evolved rapidly since the approval of imatinib. Some of the key discoveries and events include (i) the discovery of MAPK/ERK inhibitors, for example, CI-1040 (PD184352), as the first series of type III inhibitors in 2003; (ii) the approval of first dual tyrosine kinase and serine/threonine kinase inhibitor sorafenib in 2005; (iii) the description of the first series of allosteric type IVkinase inhibitor, that is,GNF-2 and analogues that inhibit Bcr–Abl through an allosteric non-ATP-competitivemode, by Gray and coworkers in 2006; (iv) the approval of the first type III inhibitor trametinib in 2013; (v) the approval of the first covalent kinase inhibitors, afatinib and ibrutinib, in 2013; and (vi) the approval of the first lipid kinase inhibitor, that is, the PI3K inhibitor idelalisib, in 2014.
By December 2016, kinase inhibitor drug discovery can leverage the structures of over 200 human kinases and 5000 kinases of all types, over 1 million publications, clinical data from more than 200 molecules currently in phase I–III trials, and post-marketing results from the approved 38 drugs.
Allgemeine Beschreibung
non-receptor tyrosine kinase|
Treatment: CML, ALL, GIST
Oral bioavailability = 98%
Elimination half-life = 20 h
Protein binding = 95%
Imatinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Imatinib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 631)Lieferanten
152459-95-5()Verwandte Suche:
- Imatinib (4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
- Imatinib free base
- Veenat
- IMatinib(STI571)
- Imantinib base
- 4-(4-Methyl-piperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaM
- IMatinib-D4
- IMatinib (Gleevec)
- 4-[(4-Methylpiperazin-1-yl)Methyl]-N-[4-Methyl-3-
- 1-Methyl-4-(4-((4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)carbaMoyl)benzyl)piperazine 1,4-dioxide
- 4,4'-(piperazine-1,4-diylbis(Methylene))bis(N-(4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)benzaMide)
- 4-Methyl-1-(4-((4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)carbaMoyl)benzyl)piperazine 1-oxide
- CGP-57148B, STI-571
- IMatinib SynonyMs 4-[(4-Methylpiperazin-1-yl)Methyl]-N-[4-Methyl-3-[(4-pyridin-3-ylpyriMidin-2-yl)aMino]phenyl]benzaMide
- 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide
- CGP057148B
- ST-1571
- IMA-3
- IMATINIB
- IMATINIB-D3
- IMATINIB 99+%
- Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
- AKOS 91378
- 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
- Imatinib, ≥99%,HPLC
- Imatinib,Gleevec,Glivec,STI-571
- Imatinib 152459-95-5
- CS-1955
- Imatinib Mesylate Impurity 5
- Imatinib>
- Imatinib USP/EP/BP
- Imatinib Raw
- 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamid e(IMATINIB FREE BASE)
- Imatinib Base (IMB-1) 4-[(4-methyl: -1-piperazininyl)methyl]-N[4-methyl-3-[[4-
{3-pyridinyl)-2-pyrimidinyl]ammo]pheny1}benzamide(For Imatinib Mesylate API)
- Imatinib API & intermediates
- N-[4-Methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]benzamide
- 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE
- Imatinib Mesilate
- matinib
- lmatinib
- Ethane,1-(2-bromoethoxy)-2-(6-methoxyethoxy)-
- 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide (Imatinib base)
- Imatinib, 10 mM in DMSO
- 152459-95-5
- 1144803-18-1
- 152459-95-9
- C29H31N7O
- API
- Antineoplastic
- Anti-cancer & immunity
- GLEVEEC
- Aromatics
- Heterocycles
- Impurities
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Pharmaceutical intermediate
- Imatinib
